Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs BRYREL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
BRYREL (bryrelimab) is a monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways including PI3K/Akt and MAPK, leading to cell cycle arrest and apoptosis in HER2-overexpressing tumor cells. It also mediates antibody-dependent cellular cytotoxicity (ADCC).
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Adjuvant treatment of HER2-overexpressing node-positive breast cancer,Metastatic HER2-positive breast cancer (first-line in combination with paclitaxel),Metastatic gastric or gastroesophageal junction adenocarcinoma (HER2-positive, in combination with cisplatin and capecitabine or 5-fluorouracil)
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
100 mg orally once daily, with or without food.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal half-life 6–8 hours in healthy adults; prolonged to 12–15 hours in moderate renal impairment (Cr Cl 30–50 m L/min) and up to 24 hours in severe impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Metabolized by general protein catabolism; no specific metabolic enzymes identified. Elimination via reticuloendothelial system.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Primarily renal excretion; 70% as unchanged drug via glomerular filtration and tubular secretion; 30% metabolized in liver to inactive metabolites, with 10% biliary excretion.
~93% bound to plasma proteins, primarily albumin.
45% bound to albumin; minor binding to α1-acid glycoprotein.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
0.8 L/kg (total body water distribution); increased in heart failure (up to 1.2 L/kg) and cirrhosis.
Oral: ~33% due to extensive first-pass metabolism.
Oral: 75% (range 60–85%)
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
GFR 30-59 m L/min: 50 mg once daily; GFR <30 m L/min or on dialysis: 25 mg once daily.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Child-Pugh class A: no adjustment; Child-Pugh class B: 50 mg once daily; Child-Pugh class C: not recommended.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Not established for patients <18 years; safety and efficacy not evaluated.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
No dose adjustment required based on age alone; consider renal function for dosing.
None
None
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Cardiomyopathy: left ventricular dysfunction, congestive heart failure, risk increased with concurrent anthracyclines. Infusion reactions: dyspnea, hypotension, angioedema. Pulmonary toxicity: interstitial lung disease, pneumonitis. Embryo-fetal toxicity: oligohydramnios, fetal renal impairment. Exacerbation of chemotherapy-induced neutropenia.
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Hypersensitivity to bryrelimab or any excipients. Severe uncontrolled hypertension. Clinically significant left ventricular ejection fraction (LVEF) reduction below 50% or below institutional lower limit of normal.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and high-calcium mineral water within 2 hours of dosing. Do not take with iron-rich foods or supplements. Grapefruit juice may increase doxycycline absorption; avoid concurrent intake. Alcohol is not contraindicated but may increase GI upset.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
BRYREL (brivaracetam) is classified as FDA Pregnancy Category C. In animal studies, brivaracetam caused developmental toxicity (increased incidence of fetal malformations and embryofetal death) at maternal toxic doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure carries a potential risk of major congenital malformations, particularly neural tube defects and orofacial clefts, based on animal data and class effect of other antiepileptic drugs. Second and third trimester exposure may be associated with adverse neurodevelopmental outcomes. Use only if potential benefit justifies risk to fetus.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Brivaracetam is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.8. Limited data suggest infant serum levels are low, but systematic studies are lacking. Due to potential adverse effects in nursing infants (drowsiness, poor feeding), caution is advised. Manufacturer recommends discontinuing breastfeeding or the drug, considering the importance of the drug to the mother.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Pregnancy can decrease brivaracetam exposure due to increased clearance (by approximately 20-30% in the third trimester). Therapeutic drug monitoring is recommended, and dose adjustments may be necessary to maintain seizure control. Consider increasing the dose by 20-30% in the third trimester, with postpartum reduction to prepregnancy dose over 1-2 weeks to avoid toxicity. Individualize based on clinical response and trough concentrations.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
BRYREL (doxycycline hyclate) is a tetracycline antibiotic with high oral bioavailability; administer with a full glass of water to reduce esophageal irritation. Avoid dairy products, antacids, iron, or bismuth subsalicylate within 2 hours of dosing due to chelation. Use sunscreen and protective clothing due to photosensitivity. Monitor for superinfection, especially candidiasis. In pediatric patients <8 years, contraindicated due to permanent tooth discoloration.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Take exactly as prescribed; complete the full course even if you feel better.,Swallow capsule whole with plenty of water; do not crush or chew.,Avoid milk, yogurt, cheese, antacids, iron supplements, or bismuth subsalicylate within 2 hours before or after taking BRYREL.,Avoid prolonged sun exposure; use sunscreen and protective clothing; report severe sunburn-like reactions.,If you miss a dose, take it as soon as you remember unless it's near the time of the next dose; do not double the dose.,Contact your healthcare provider if you develop watery or bloody diarrhea, severe headache, blurred vision, or signs of liver problems (dark urine, yellowing skin/eyes).,Do not use if you are pregnant, planning to become pregnant, or breastfeeding unless directed by your doctor.,Store at room temperature away from moisture and heat; keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs BRYREL, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. BRYREL is a Opioid Partial Agonist that works by BRYREL (bryrelimab) is a monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways including PI3K/Akt and MAPK, leading to cell cycle arrest and apoptosis in HER2-overexpressing tumor cells. It also mediates antibody-dependent cellular cytotoxicity (ADCC).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and BRYREL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of BRYREL is: 100 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and BRYREL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . BRYREL is classified as Category C. BRYREL (brivaracetam) is classified as FDA Pregnancy Category C. In animal studies, brivaracetam caused developmental toxicity (increased incidence of fetal malformations and embry. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.